Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Umang Swami"'
Autor:
Morgan B. Marshall, Kassandra Dindinger-Hill, Umang Swami, Stephanie Lyden, Alejandro Sanchez
Publikováno v:
Urology Case Reports, Vol 48, Iss , Pp 102427- (2023)
A 25-year-old male was admitted to the neurological intensive care unit for neurologic deterioration, likely caused by a paraneoplastic syndrome secondary to testicular malignancy. He experienced spontaneous rupture and hemorrhage of his testicular m
Externí odkaz:
https://doaj.org/article/ed87c797df9a4e4ebf67ac8f35cfdc08
Autor:
Haoran Li, Kamal Kant Sahu, Shruti Adidam Kumar, Blake Nordblad, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Publikováno v:
Heliyon, Vol 8, Iss 9, Pp e10583- (2022)
Background: COVID-19 vaccination is one of the pivotal key tools against the ongoing pandemic, but its acceptance relies on efficacy and safety data among various populations, including patients with cancers. However, there is limited data on serocon
Externí odkaz:
https://doaj.org/article/8436bd9676a84a87929abb313c09f0f8
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100325- (2021)
Metastatic bladder cancer has poor overall survival. Though systemic therapies have shown to improve overall survival, real-world studies have shown that more than half of the patients do not receive any systemic therapy, while only around 15–20% r
Externí odkaz:
https://doaj.org/article/dadef45b5f524c29adbfc960b086c70a
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100384- (2021)
Prostate cancer affects one in nine men and once metastatic is incurable. The treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over the last decade with the addition of upfront intensification with novel hormo
Externí odkaz:
https://doaj.org/article/ea85c72633ce481c88c78f1929c3e0dd
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss , Pp 100480- (2021)
Cancers with mutations in BRCA2 have defective DNA repair capacity which is potentially targetable with poly-ADP(ribose) polymera se (PARP) inhibitors such as olaparib and rucaparib. However, the development of a secondary mutation that restores BRCA
Externí odkaz:
https://doaj.org/article/3ffddd9a193f4f66aa5b2ec72085f76a
Autor:
Umang Swami, Neeraj Agarwal
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100205- (2020)
Since 2018, apalutamide, darolutamide, and enzalutamide have been approved for the treatment of men with non-metastatic castration-resistant prostate cancer (M0CRPC). These approvals were based on the results of three separate randomized, placebo-con
Externí odkaz:
https://doaj.org/article/06b53caa8e3c42e0b98da85edaea2c99
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100325-(2021)
Metastatic bladder cancer has poor overall survival. Though systemic therapies have shown to improve overall survival, real-world studies have shown that more than half of the patients do not receive any systemic therapy, while only around 15-20% rec
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss, Pp 100480-(2021)
Cancers with mutations in BRCA2 have defective DNA repair capacity which is potentially targetable with poly-ADP(ribose) polymera se (PARP) inhibitors such as olaparib and rucaparib. However, the development of a secondary mutation that restores BRCA